Vireo Health International (CSE: VREO) (OTCQX: VREOF) - Investor Dashboard

Vireo Health
CSE Ticker: VREO
Market Focus: United States
Classification: Vertically Integrated
Country: United States
Employees: > 400 (October 2020)
Established: 2012
CEO: Kyle Kingsley, M.D.


Fiscal Year-End: Dec 31
Auditor: Davidson & Company LLP
Exchanges: CSE, OTC
Sector: Healthcare
State with Operations: 9
Headquarters: Minneapolis, MN

Financials (09/30/20)

Cash on hand: $16.3 million
Fixed Investment: $15.2 million
Shareholders’ Equity: $71.8 million
Revenues – Last Quarter: $11.9 million
Adj. Gross Margin : 42.7%
EPS : -$0.00

Capital Structure (11/30/20)

Last Financing: 13.7 million units at C$0.77
As-converted Shares: 98.9 million
Warrants: 30.3 million
Options: 24.7 million
Diluted Shares: 153.9 million


Company Brief

Vireo Health International, Inc. (CSE: VREO) (OTCQX: VREOF) is an American leading science-focused, multi-state cannabis company. The Company has operations in nine states— Arizona, Maryland, Minnesota, Massachusetts, New Mexico, New York, Nevada, Pennsylvania, and Rhode Island —and Puerto Rico. In 2020, the company is realigning its strategy to focus on near-term profitability in its six core medical markets: Arizona, Maryland, Minnesota, New Mexico, New York and Pennsylvania

Vireo’s physician-led team of more than 400 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries.

Featured Video

Using Science to Enable Cannabis Substitution for Opioids, Tobacco and Alcohol.


  • Asset portfolio in strategic U.S. states with revenue growth tailwinds expected from recreational legalization over the next 6 to 24 months
  • Track record of winning merit-based licenses
  • 11 manufacturing licenses and 32 dispensary licenses
  • Vireo’s retail outlets are being transformed and rebranded to “Green Goods” dispensaries
  • To date, successfully raised $113 million in debt and equity financing to support its multi-state operations and growth plans
  • Product lines including: Vireo, Option Gels, 1937, Lite Bud and terpene-enhanced flower Amplifi

Growth Strategy

  • Operating strategy to focus on near-term profitability in six core medical markets: Arizona, Maryland, Minnesota, New Mexico, New York and Pennsylvania
  • Plans to pursue immediately accretive M&A opportunities to augment existing market position
  • Entered the industrial hemp market and holds two hemp licenses through its wholly-owned subsidiaries
  • Wholesale platform through partnership with Leaf Trade
  • Its extensive intellectual property portfolio has been developed to build a durable long-term business model that differs from peers


  • Focused on transformative intellectual property ranging from novel product formulations, to agricultural scale cannabinoid production processes and equipment
  • Subsidiary Resurgent Biosciences to commercialize IP
  • Eight research partnerships and 12 patents-pending
  • Vireo plans to leverage its medical, scientific and operational expertise to efficiently expand its operation in existing markets and enter new markets
  • The company is focused on prudent capital allocation

Institutional Analyst Coverage

Graeme Kreindler, CPA, CA
Eight Capital

Matt Bottomley, CPA, CA, CBV
Canaccord Genuity Corp.

Curated Stories & News

Visit Vireo Health International, Inc.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Vireo Health International, Inc. is a client of NCV Media, LLC. Read our full disclaimer.